These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

137 related articles for article (PubMed ID: 15473596)

  • 1. Interstitial pneumonitis in a patient with melanoma treated with the high dose interferon alpha 2b regimen.
    Siegelmann-Danieli N; Bardo M; Law A; Fisk D; Bernath A
    Isr Med Assoc J; 2004 Oct; 6(10):636-7. PubMed ID: 15473596
    [No Abstract]   [Full Text] [Related]  

  • 2. Interstitial pneumonitis and lung fibrosis during adjuvant treatment of melanoma with interferon alpha according to the Kirkwood schedule.
    Puente Vázquez J; Moreno Antón F; Grande Pulido E; López Tarruella-Cobo S; Pérez Segura P; Díaz-Rubio E
    Dermatology; 2005; 210(3):247-9. PubMed ID: 15785060
    [No Abstract]   [Full Text] [Related]  

  • 3. Depression in hospitalized patients with malignant melanoma treated with interferon-alpha-2b: primary to induced disorders.
    Navinés R; Gómez-Gil E; Puig S; Baeza I; De Pablo J; Martín-Santos R
    Eur J Dermatol; 2009; 19(6):611-5. PubMed ID: 19709980
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Grand mal seizure induced by interferon-alpha-2b.
    Kors C; Milling A; Hofmann M; Sterry W; Trefzer U
    J Eur Acad Dermatol Venereol; 2006 Apr; 20(4):473-4. PubMed ID: 16643159
    [No Abstract]   [Full Text] [Related]  

  • 5. Delayed wound healing following treatment with low-dose interferon alfa-2b for cutaneous melanoma.
    Ammoury AF; El Sayed F; Bazex J
    Arch Dermatol; 2007 Oct; 143(10):1339-40. PubMed ID: 17938359
    [No Abstract]   [Full Text] [Related]  

  • 6. Urticaria, angioedema and dyspnoea in adjuvant therapy of melanoma with interferon alpha-2b.
    Helbig D; Simon JC; Treudler R
    Acta Derm Venereol; 2010 May; 90(3):308-9. PubMed ID: 20526557
    [No Abstract]   [Full Text] [Related]  

  • 7. Livedo reticularis associated with interferon alpha therapy in two melanoma patients.
    Ruiz-Genao DP; García-F-Villalta MJ; Hernández-Núñez A; Ríos-Buceta L; Fernández-Herrera J; García-Díez A
    J Eur Acad Dermatol Venereol; 2005 Mar; 19(2):252-4. PubMed ID: 15752306
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Early signs of liver failure after low-dose interferon alfa-2b for cutaneous melanoma.
    Ammoury A; El Sayed F; Farah C; Bazex J
    J Am Acad Dermatol; 2008 Mar; 58(3):532-3. PubMed ID: 18280369
    [No Abstract]   [Full Text] [Related]  

  • 9. Livedo reticularis: a side effect of interferon therapy in a pediatric patient with melanoma.
    Fox M; Tahan S; Kim CC
    Pediatr Dermatol; 2012; 29(3):333-5. PubMed ID: 21575046
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Mediastinal sarcoidosis induced by high-dose alpha-2-interferon therapy in a patient with malignant melanoma.
    Massaguer S; Sánchez M; Castel T
    Eur Radiol; 2004 Sep; 14(9):1716-7. PubMed ID: 14740162
    [No Abstract]   [Full Text] [Related]  

  • 11. Severe action tremor related to interferon-alpha 2b therapy for malignant melanoma.
    Nishihori T; Abdo-Matkiwsky M; Fleishman SB; Blum RH
    Am J Clin Oncol; 2005 Oct; 28(5):526. PubMed ID: 16199995
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Meyerson's phenomenon in a patient affected by high-risk melanoma under treatment with interferon-α.
    Zonta E; Chiarion V; Zarian H; Peserico A; Alaibac M
    Melanoma Res; 2012 Jun; 22(3):284-5. PubMed ID: 22543678
    [No Abstract]   [Full Text] [Related]  

  • 13. Cutaneous sarcoidosis by interferon therapy in a patient with melanoma.
    Alonso-Pérez A; Ballestero-Díez M; Fraga J; García-Díez A; Fernández-Herrera J
    J Eur Acad Dermatol Venereol; 2006 Nov; 20(10):1328-9. PubMed ID: 17062055
    [No Abstract]   [Full Text] [Related]  

  • 14. The feasibility of adjuvant interferon alpha-2b in children with high-risk melanoma.
    Navid F; Furman WL; Fleming M; Rao BN; Kovach S; Billups CA; Cain AM; Amonette R; Jenkins JJ; Pappo AS
    Cancer; 2005 Feb; 103(4):780-7. PubMed ID: 15660397
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Nursing management of patients with malignant melanoma receiving adjuvant alpha interferon-2b.
    Kiley KE; Gale DM
    Clin J Oncol Nurs; 1998 Jan; 2(1):11-6. PubMed ID: 9481251
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Vitiligo and morphea: autoimmune cutaneous side effects of interferon treatment].
    Martínez-García S; Fernández-Ballesteros MD; Segura-Palacios JM
    Actas Dermosifiliogr; 2012 Apr; 103(3):250-1. PubMed ID: 22056259
    [No Abstract]   [Full Text] [Related]  

  • 17. Lipoatrophy associated with interferon alfa adjuvant therapy for melanoma.
    Vallés L; González M; Polo I; Enguita AB; Vanaclocha F; Ortiz-Romero PL
    Arch Dermatol; 2009 Jan; 145(1):98-9. PubMed ID: 19153363
    [No Abstract]   [Full Text] [Related]  

  • 18. Lichen planus induced by interferon-alpha-2B therapy in a patient with cutaneous malignant melanoma.
    Herrera Saval A; Camacho Martínez F
    Acta Derm Venereol; 1999 Sep; 79(5):395. PubMed ID: 10494726
    [No Abstract]   [Full Text] [Related]  

  • 19. [Induced interstitial pneumonitis: role of pegylated interferon alpha 2b].
    Rocca P; Dumortier J; Tanière P; Duperret S; Vial T; Cottin V; Delafosse B; Scoazec JY; Boillot O
    Gastroenterol Clin Biol; 2002 Apr; 26(4):405-8. PubMed ID: 12070414
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Rheumatoid arthritis complicating adjuvant interferon-alpha therapy for malignant melanoma.
    Johnson DM; Hayat SQ; Burton GV
    J Rheumatol; 1999 Apr; 26(4):1009-10. PubMed ID: 10229440
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 7.